Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tyrosine--tRNA ligase, cytoplasmic (YARS1), also known as tyrosyl-tRNA synthetase or TyrRS, is an essential enzyme that catalyzes the two-step attachment of L‑tyrosine to its cognate tRNATyr during protein biosynthesis. This reaction is fundamental for translating genetic information into proteins by ensuring accurate incorporation of tyrosine at positions specified by mRNAs. The enzyme first activates tyrosine with ATP forming a Tyr‑AMP intermediate before transferring it onto tRNATyr. Beyond this canonical role in translation, YARS1 has additional functions including regulation of nuclear poly(ADP-ribosyl)ation through interaction with PARP1—especially upon binding small molecules such as resveratrol—and may exert cytokine-like or proangiogenic effects via proteolytic fragments outside the context of protein synthesis[1][3][4][6].
For inhibitors like resveratrol: - Inhibition of aminoacylation activity by direct binding, leading to relocalization from cytoplasm to nucleus where it stimulates PARP1-mediated poly(ADP-ribosyl)ation independent of aminoacylation function[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tyrosine--tRNA ligase, cytoplasmic (YARS1 (also commonly referred to as TyrRS)).